Price T Rowe Associates Inc Lian Bio Transaction History

Price T Rowe Associates Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.49 - $2.46 $166,057 - $274,162	-111,448 Reduced 4.11%	2,598,766 $3.87 Million
Q2 2023 Aug 14, 2023	BUY	$1.79 - $2.85 $308,962 - $491,924	172,605 Added 6.8%	2,710,214 $6.18 Million
Q1 2023 May 15, 2023	SELL	$1.57 - $2.66 $225,904 - $382,742	-143,888 Reduced 5.37%	2,537,609 $4.95 Million
Q4 2022 Feb 14, 2023	SELL	$1.14 - $2.11 $161,150 - $298,269	-141,360 Reduced 5.01%	2,681,497 $4.4 Million
Q3 2022 Nov 14, 2022	BUY	$1.87 - $3.0 $1.3 Million - $2.09 Million	695,979 Added 32.72%	2,822,857 $5.62 Million
Q2 2022 Aug 15, 2022	SELL	$2.15 - $6.01 $248,348 - $694,221	-115,511 Reduced 5.15%	2,126,878 $4.59 Million
Q4 2021 Feb 14, 2022	BUY	$6.14 - $16.2 $13.8 Million - $36.3 Million	2,242,389 New	2,242,389 $13.4 Million

1.1M

Ticker LIAN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,354,000
Market Cap $32.5M
Description
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with p...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.